10/7
08:17 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
9/9
02:14 pm
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/9
01:15 pm
kalv
Rating for KALV
Low
Report
Rating for KALV
9/6
08:08 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
9/6
08:08 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
9/6
05:31 am
kalv
Rating for KALV
Medium
Report
Rating for KALV
9/6
05:31 am
kalv
Rating for KALV
Medium
Report
Rating for KALV
8/27
07:54 am
kalv
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.